Panacea Biotec Ltd.

NSE: PANACEABIO BSE: 531349 SECTOR: Pharmaceuticals & Drugs  19k   80   17

202.60
+1.15 (0.57%)
NSE: Today, 03:58 PM

Price Summary

Today's High

₹ 205

Today's Low

₹ 196.95

52 Week High

₹ 449

52 Week Low

₹ 165.3

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1240.94 Cr.

Enterprise Value

1217.06 Cr.

No. of Shares

6.13 Cr.

P/E

0

P/B

2.68

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  75.46

CASH

88.96 Cr.

DEBT

65.08 Cr.

Promoter Holding

73.59 %

EPS (TTM)

₹  -10.16

Sales Growth

-29.84%

ROE

-2.11 %

ROCE

-0.7%

Profit Growth

90.57 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-29.84%
3 Year-15.73%
5 Year-11.89%

Profit Growth

1 Year90.57%
3 Year21.62%
5 Year-275.39%

ROE%

1 Year-2.11%
3 Year-6.48%
5 Year-12.4%

ROCE %

1 Year-0.7%
3 Year3.97%
5 Year3.27%

Debt/Equity

0.1281

Price to Cash Flow

32.43

Interest Cover Ratio

-0.71344951443395

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 73.59 94.27
Jun 2021 73.59 94.27
Mar 2021 73.59 94.27
Dec 2020 73.59 69.36
Sep 2020 73.59 69.36
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -18.6288267680943 days.

 Limitations

  • The company has shown a poor revenue growth of -15.7349196325503% for the Past 3 years.
  • Company has a poor ROE of -6.48450711155097% over the past 3 years.
  • Promoter pledging has increased from 73.59% to 94.27% in 1 quarter.
  • Company has a poor ROCE of 3.96586385753626% over the past 3 years
  • Company has low Interest coverage ratio of -0.71344951443395.
  • Company has contingent liabilities of 406.993 Cr.
  • The company has a low EBITDA margin of -0.790020756858169% over the past 5 years.
  • Promoter pledging is high as 94.27%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 118.2 69.02 79.86 36.26 119.26
Total Expenditure 102.34 65.75 95.97 55.67 136.71
Operating Profit 15.86 3.27 -16.11 -19.41 -17.45
Other Income 2.95 7.17 7.75 4.15 3.47
Interest 1.99 1.89 1.86 1.78 1.91
Depreciation 6.69 6.64 6.57 6.43 6.48
Exceptional Items 0 0 0 0 0
Profit Before Tax 10.13 1.91 -16.79 -23.47 -22.37
Tax 0.01 0.01 1.52 0 0
Profit After Tax 10.12 1.9 -18.31 -23.47 -22.37
Adjusted EPS (Rs) 1.65 0.31 -2.99 -3.83 -3.65

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 530.09 574.19 444.16 489.68 343.56
Total Expenditure 460.6 492.76 590.77 479.63 343.1
Operating Profit 69.48 81.43 -146.61 10.05 0.46
Other Income 53.66 17.62 8.12 43.91 20.75
Interest 103.5 103.23 104.63 147.25 7.52
Depreciation 66.15 57.05 53.71 27.29 26.57
Exceptional Items -37.54 0 334.01 -15.4 0
Profit Before Tax -84.04 -61.23 37.18 -135.97 -12.88
Tax -11.38 10.64 10.61 17.1 1.56
Net Profit -72.66 -71.88 26.57 -153.07 -14.44
Adjusted EPS (Rs.) -11.86 -11.73 4.34 -24.99 -2.36

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 6.13 6.13 6.13 6.13 6.13
Total Reserves 449.7 381.97 412.35 886.61 502.04
Borrowings 714.06 570.71 88.3 60.43 62.08
Other N/C liabilities 160.29 177.62 165.16 186.72 190.71
Current liabilities 589.91 685.27 921.09 167.35 200.8
Total Liabilities 1920.07 1821.69 1593.02 1307.23 961.76
Assets
Net Block 942.02 890.93 496.44 447.29 398.44
Capital WIP 5.98 4.76 2.95 3.66 12.93
Intangible WIP 21.71 32.4 0.15 0.08 0.04
Investments 344.88 344.88 2.54 54.53 66.08
Loans & Advances 195.57 194.69 173.95 186.5 187.45
Other N/C Assets 0.55 0.39 0.89 0.85 4.27
Current Assets 409.37 353.65 916.11 614.32 292.55
Total Assets 1920.07 1821.69 1593.02 1307.23 961.76
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations -84.04 -61.23 37.18 -135.97 -12.88
Adjustment 184.07 160.4 -67.89 204.95 31.82
Changes in Assets & Liabilities -2.52 73.35 137.45 -143.93 20.3
Tax Paid 6.32 -0.45 0.42 -7.9 -0.98
Operating Cash Flow 103.84 172.06 107.16 -82.86 38.27
Investing Cash Flow -17.92 -2.73 -10.27 -16.58 -37.32
Financing Cash Flow -91.06 -163.67 -98.45 109.39 -7.2
Net Cash Flow -5.15 5.66 -1.57 9.96 -6.26

Corporate Actions

Investors Details

PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Promoters 73.59 73.59 73.59 73.59 73.59
dr. rajesh jain 10.14 10.14 10.14 10.14 10.14
mrs. sunanda jain 10.85 10.85 10.85 10.85 1.53
mr. sandeep jain 7.82 7.82 7.82 7.82 7.82
mr. ravinder jain - - - - 9.33
mr. soshil kumar j... 8.16 8.16 8.16 8.16 8.16
ravinder jain (huf) 6.75 6.75 6.75 6.75 6.75
sandeep jain (huf) 6.70 6.70 6.70 6.70 6.70
rajesh jain (huf) 6.12 6.12 6.12 6.12 6.61
mrs. nirmala jain 4.10 4.10 4.10 4.10 4.10
first lucre partne... - - - - 3.68
soshil kumar jain ... 3.68 3.68 3.68 3.68 3.68
first lucre partne... 3.68 3.68 3.68 3.68 -
mrs. meena jain 1.46 1.46 1.46 1.46 1.46
mrs. pamilla jain 1.33 1.33 1.33 1.33 1.33
mr. sumit jain 0.59 0.59 0.59 0.59 0.59
mrs. radhika jain 0.58 0.58 0.58 0.58 0.58
mrs. priyanka jain 0.52 0.52 0.52 0.52 0.52
mr. ankesh jain 0.50 0.50 0.50 0.50 0.50
mr. harshet jain 0.49 0.49 0.49 0.49 0.49
second lucre partn... 0.09 0.09 0.09 0.09 -
second lucre partn... - - - - 0.09
PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Investors 26.41 26.41 26.41 26.41 26.41
serum institute of... 9.43 9.43 - - 14.58
serum institute of... - - 9.43 9.43 -
adar cyrus poonawa... 5.15 5.15 5.15 5.15 -
icici prudential p... 1.19 1.19 1.59 1.59 -
apoorva realtors &... 1.24 1.14 - - -
apporva realtors &... - - - - 1.19
gain premium limit... - - - - 1.04
overseas corporate... - - - - 1.04
depository partici... - - - 0.25 -
iepf 0.19 0.19 0.19 0.19 -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ1FY22 29 Jul 2021

Panacea Biotec Stock Price Analysis and Quick Research Report. Is Panacea Biotec an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Panacea Biotec and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 38.266 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Panacea Biotec has a Debt to Equity ratio of 0.1281 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Panacea Biotec , the EPS growth was 90.5657542300908 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Panacea Biotec has OPM of 0.133894136310063 % which is a bad sign for profitability.
     
  • ROE: Panacea Biotec have a poor ROE of -2.10987077936356 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Panacea Biotec

X